Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment

Siervi, Silvia De; Cannito, Stefania; Turato, Cristian

doi:10.3390/ijms241310633

Cited by 3 publications

(1 citation statement)

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis C is a major global health challenge, being one of the primary causes of liver disease [ 170 , 171 ]. The WHO’s latest estimates report that there are approximately 50 million people infected with HCV globally, with around 1 million new infections each year and about 242,000 deaths annually attributed to HCV-related complications [ 4 ].…”

Section: Epidemiology Transmission and Global Figures Of Hepatitis Cmentioning

confidence: 99%

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

Sallam,

Khalil

2024

Microorganisms

View full text Add to dashboard Cite

Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50 million people were living with chronic hepatitis C based on the World Health Organization as of 2024, contributing extensively to global morbidity and mortality. The advent and approval of several direct-acting antiviral (DAA) regimens significantly improved HCV treatment, offering potentially high rates of cure for chronic hepatitis C. However, the promising aim of eventual HCV eradication remains challenging. Key challenges include the variability in DAA access across different regions, slightly variable response rates to DAAs across diverse patient populations and HCV genotypes/subtypes, and the emergence of resistance-associated substitutions (RASs), potentially conferring resistance to DAAs. Therefore, periodic reassessment of current HCV knowledge is needed. An up-to-date review on HCV is also necessitated based on the observed shifts in HCV epidemiological trends, continuous development and approval of therapeutic strategies, and changes in public health policies. Thus, the current comprehensive review aimed to integrate the latest knowledge on the epidemiology, pathophysiology, diagnostic approaches, treatment options and preventive strategies for HCV, with a particular focus on the current challenges associated with RASs and ongoing efforts in vaccine development. This review sought to provide healthcare professionals, researchers, and policymakers with the necessary insights to address the HCV burden more effectively. We aimed to highlight the progress made in managing and preventing HCV infection and to highlight the persistent barriers challenging the prevention of HCV infection. The overarching goal was to align with global health objectives towards reducing the burden of chronic hepatitis, aiming for its eventual elimination as a public health threat by 2030.

show abstract

Section: Epidemiology Transmission and Global Figures Of Hepatitis Cmentioning

confidence: 99%

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

Sallam,

Khalil

2024

Microorganisms

View full text Add to dashboard Cite

show abstract

The impact of formaldehyde exposure on lung inflammatory disorders: Insights into asthma, bronchitis, and pulmonary fibrosis

Bhat,

Afzal,

Goyal

et al. 2024

Chemico-Biological Interactions

View full text Add to dashboard Cite

Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study

Zhang,

Luo,

et al. 2024

World J Hepatol

View full text Add to dashboard Cite

BACKGROUND Acute-on-chronic liver disease (AoCLD) accounts for the majority of patients hospitalized in the Department of Hepatology or Infectious Diseases. AIM To explore the characterization of AoCLD to provide theoretical guidance for the accurate diagnosis and prognosis of AoCLD. METHODS Patients with AoCLD from the Chinese Acute-on-Chronic Liver Failure (ACLF) study cohort were included in this study. The clinical characteristics and outcomes, and the 90-d survival rate associated with each clinical type of AoCLD were analyzed, using the Kaplan-Meier method and the log-rank test. RESULTS A total of 3375 patients with AoCLD were enrolled, including 1679 (49.7%) patients with liver cirrhosis acute decompensation (LC-AD), 850 (25.2%) patients with ACLF, 577 (17.1%) patients with chronic hepatitis acute exacerbation (CHAE), and 269 (8.0%) patients with liver cirrhosis active phase (LC-A). The most common cause of chronic liver disease (CLD) was HBV infection (71.4%). The most common precipitants of AoCLD was bacterial infection (22.8%). The 90-d mortality rates of each clinical subtype of AoCLD were 43.4% (232/535) for type-C ACLF, 36.0% (36/100) for type-B ACLF, 27.0% (58/215) for type-A ACLF, 9.0% (151/1679) for LC-AD, 3.0% (8/269) for LC-A, and 1.2% (7/577) for CHAE. CONCLUSION HBV infection is the main cause of CLD, and bacterial infection is the main precipitant of AoCLD. The most common clinical type of AoCLD is LC-AD. Early diagnosis and timely intervention are needed to reduce the mortality of patients with LC-AD or ACLF.

show abstract

Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment

Abstract: Chronic liver disease (CLD) is a major global health threat and has emerged as a leading cause of human death [...]

Cited by 3 publications

References 14 publications

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

The impact of formaldehyde exposure on lung inflammatory disorders: Insights into asthma, bronchitis, and pulmonary fibrosis

Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study

Contact Info

Product

Resources

About